PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-27.92%
Negative net income growth while AGEN stands at 311.07%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.10%
Some D&A expansion while AGEN is negative at -2.44%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-10.46%
Both cut yoy SBC, with AGEN at -14.28%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
292.72%
Slight usage while AGEN is negative at -2792.40%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
215.28%
Lower AP growth vs. AGEN's 1095.60%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
292.72%
Some yoy usage while AGEN is negative at -1180.00%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-67.58%
Both negative yoy, with AGEN at -82.59%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-21.90%
Negative yoy CFO while AGEN is 336.47%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-11.48%
Both yoy lines negative, with AGEN at -886.17%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.48%
Both yoy lines negative, with AGEN at -1106.39%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-59.52%
Negative yoy issuance while AGEN is 746.62%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.